Kymera Therapeutics(KYMR) - 2024 Q3 - Quarterly Results

Exhibit 99.1 ¦KYMERA Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; completion of both expanded trials expected by mid-2026 KT-295, a new TYK2 degrader, selected as the deve ...